THE CASSIOPEA STORY

OUR SKIN TELLS A STORY

Our appearance is more than just our exterior; it’s what we show the world. It reflects where we’ve been and how we are feeling. It’s an important part of who we are and how we feel about ourselves.

Cassiopea is on a mission to be the catalyst for a new era of treatments in dermatology by developing new products with the ability to help millions of patients.

 

That’s why we are driven to pursue better dermatology

Cassiopea S.p.A. is listed on the Swiss stock exchange (ticker: SKIN) with the vision of building a leading, fully integrated dermatology company. Cassiopea, Inc., our United States subsidiary, was created with the mission to commercialize Cassiopea’s products in the United States.

At Cassiopea, we are driven by the goal to treat persistent skin conditions, like acne, that have a long-term physical and emotional impact on lives and self-esteem.

Our current portfolio comprises 4 potentially groundbreaking clinical candidates, for which Cassiopea owns the worldwide rights. These product candidates are based on three new chemical entities (NCEs) and target unmet medical needs and opportunities in the medical dermatology market.

What do we believe?

That we are important partners in the delivery of patient care, and that our role includes drug development, education, service, access, and support to ensure that sufferers get the treatment options they need.

Why dermatology?

Because dermatology matters to healthcare providers who are forward-thinking and searching for new innovation to address essential conditions like acne and alopecia. When there’s progress in dermatology, magic happens. Patients gain confidence, change their outlook, and live better lives.

OUR STRATEGY

Build our team

Cassiopea is led by a team that has a wealth of experience in drug development commercialization and dermatology and passion for the category. This team will expand to include others who are just as committed and devoted to new breakthroughs to positively impact dermatologists and their patients.

Research and development

Several of our pipeline products have completed Phase II studies. We expect to continue to progress these programs through Phase III trials for approval and commercialization. We strive to maintain a well-balanced portfolio of product candidates across various stages of development. We intend to focus on product candidates that have demonstrated attractive profiles in early clinical testing as well as those in an earlier stage that have substantial commercial opportunities.

Commercialization

We intend to expand our portfolio with product candidates in different therapeutic areas. We may also seek to acquire dermatology products that are already approved for marketing. Our goal is to bring these late-stage products to market for the benefit of both physicians and patients.

OUR LEADERSHIP

BOARD OF DIRECTORS

JAN DE VRIES

Chairperson, Board of Directors

After joining in 2015, de Vries has served as Chair of the Cassiopea Board of Directors. He is also Chair of the Board of Artax Inc., is a member of the Scientific Advisory Board of AnaptysBio, Inc., and is a Board Member and CEO of Amsterdam-based AIMM Therapeutics BV.

De Vries has decades of experience across research and development in academia, biotechnology, and pharmaceutical industries. He is the co- founder and CEO of Tr1X, a biotech company based in California. Prior to that, de Vries was the CEO of AIMM Therapeutics and currently serves as AIMM’s Chairman of the Board. Before joining AIMM, de Vries was Senior Vice President, Drug Discovery and Early Development at Novartis and Head of the Novartis Research Institutes for Biomedical Research in Basel, Switzerland. He was also Global Head of the Therapeutic Area of Autoimmunity, Inflammation, and Transplantation in Basel and Vienna. At Novartis, he steered the discovery and early development of dozens of compounds, both low molecular weight, and biologics including the marketed drugs Elidel®, Ilaris®, Gilenya® , Cosentyx®, and Maizent®. De Vries joined Novartis from the California-based DNAX Research Institute for Molecular Biological Research (acquired by Schering-Plough and Merck & Co), where he was Director of Immunology. Prior to that, he was Co-Director of the Schering–Plough Institute for Immunological Research in Lyon, France.

De Vries is a member of the scientific advisory boards of several private and public biotechnology companies. He started his career in academia at the Netherlands Cancer Institute in Amsterdam, where he was Head of the Department of Immunology. De Vries has published more than 300 scientific papers in peer-reviewed journals and holds 20 patents. He earned an MSc degree in Biology/Biochemistry from the University of Utrecht, a PhD degree in Immunology from the University of Amsterdam, and completed his Post-Doctoral studies with John Mendelsohn at the University of California, San Diego.

DIANA HARBORT

Chief Executive Officer

As a board member and the Chief Executive Officer of Cassiopea since its inception in 2015, Diana Harbort brings 30 years of cross-functional experience in the pharmaceutical industry, including 20 years in the dermatology sector. As CEO, she executed the IPO in 2015, the largest healthcare IPO on the Swiss Stock Exchange (SIX) since 2000, recruited and placed the corporate leadership team and built the processes and growth plans for the company.

Harbort has held executive positions at leading pharmaceutical companies, including 17 years at Medicis Pharmaceutical Corporation, an industry leading dermatology and aesthetics company, ultimately serving as the Vice President of Corporate Development. In this role, she in-licensed or acquired most of the company’s products and pipeline before its acquisition by Valeant for $2.3B in 2012. Earlier in her career, she spent 10 years in various roles at Abbott Laboratories, in marketing, business development and operations across Abbott’s pharmaceutical, hospital products and diagnostic divisions. She was also a highly sought-out advisor and independent consultant immediately prior to joining Cassiopea. Throughout her career, she has evaluated over 3000 opportunities in the dermatology space and negotiated over 75 agreements, becoming an expert across a broad range of dermatology diseases and markets.

A high-energy, results-oriented leader, Harbort thrives on execution and relationship building, both within the company and throughout the industry. She graduated with a bachelor’s degree in Business Administration from the University of Wisconsin-Whitewater and received an MBA in Marketing and Management from the Northwestern University Kellogg School of Management. She currently is a member of the American Academy of Dermatology, the Women’s Dermatological Society and a volunteer senior leader in the Tony Robbin’s organization. Harbort is a champion for health and wellness, mother of two, personal development advocate and international mission trip leader.

ØYVIND BJORDAL

Board Member

Øyvind Bjordal has brought his substantial financial expertise to Cassiopea’s Board of Directors since its inception in 2015. Bjordal currently serves as Managing Director and Head of Switzerland of Lincoln International, a corporate finance advisory company based in Zurich, Switzerland.

Previously, Norwegian-born Bjordal was Managing Director of a group of corporate financiers that worked with Arthur Anderson, Ernst & Young, Sal Oppenheim, and Leonardo & Co. He was also a member of the corporate finance team at UBS Investment Banking, working on transactions throughout Europe, including several privatization assignments in the telecoms sector.

Bjordal received a degree in Business Administration from the University of Fribourg in Switzerland.

PIERPAOLO GUZZO

Board Member

A member of the Cassiopea Board of Directors since 2015, Guzzo is the founder and CEO of management consulting and investing firm EQValue Partners. He is also managing partner of the Rome-based consulting firm BOCG Associati.

Guzzo previously served as director at PM & Partners SpA, a private equity fund focused on Italian companies, and was an investment manager at ABN AMRO Private Equity. He began his career at Arthur Andersen, working in the audit and business-consulting field, and was a member of the mergers and acquisitions team at SOFIPA, an Italian merchant bank. Over the last 20 years, he has been regularly appointed in the corporate bodies of several Italian SME and large companies.

Guzzo graduated with a degree in Business Administration from the Sapienza University of Rome. He is a Certified Public Accountant (“Dottore Commercialista”) and External Auditor (“Revisore Contabile”) and member of Ned Community, the Italian Association of Non-Executive and Independent Directors.

MAURIZIO BALDASSARINI

Board Member

Baldassarini is our Chartered Accountant and Auditor who has served on the Cassiopea Board of Directors since 2018. A technical advisor to the Court of Rome, he specializes in business valuation, financial-economic analysis, and business/investment plan development. He is also a founding partner at BOCG Associati, a management-consulting firm based in Italy.

During his career, Baldassarini has assisted with multiple merger and acquisition projects as well as corporate restructurings, serving primarily as a business and financial advisor. He has been appointed as an expert witness to the court of law in the field of transformations and corporate mergers and holds duties as board administrator and chair of the Italian Statutory Board of Auditors.

Baldassarini was a professor of Corporate Finance at the Sapienza University of Rome and a professor at various training institutions in Italy. He received a degree from the University of Rome in Economics and Business and has published several scientific monographs in corporate finance.

DR. HANS CHRISTOPH TANNER

Chief Financial Officer, Head of Investor Relations

Dr. Hans Christoph Tanner is the Chief Financial Officer (CFO) and Head of Investor Relations for Cassiopea, joining the company in 2015. As CFO, he oversees Finance and Investor Relations for the organization. Tanner also serves as Head of the Transactions Office for Cosmo Pharmaceuticals, the largest shareholder of Cassiopea. Tanner was CFO and Head of Investor Relations of Cosmo Pharmaceuticals since 2006. He has over 40 years of experience in finance, both in capital market transactions, as well as mergers and acquisitions.

Tanner spent more than 20 years of his career at UBS, initially assigned to various management roles in the United States and Spain. He moved on to become the Chief of Staff of International Corporate Banking and, subsequently, Head of International Corporate Banking for Asia, Australia, Africa and Southern Europe. In 1992, he was appointed as the Head of Corporate Finance and Capital Markets at UBS in Zurich. Following the merger of UBS with SBC, he left UBS in 1998 to become partners with Dr. Ernst Müller-Möhl and together, with others, they cofounded the 20 Minuten group of newspapers as well as A&A Active Investor, a listed investment company. From 2002 to 2006 he was a corporate financial advisor and participated in numerous fundraising activities, including the private placement of Cosmo Holding, S.p.A. As a banker, he was the Global Coordinator for 12 international IPOs, three privatizations and two demutualizations. Additionally, he led the IPOs of Cosmo Pharmaceuticals and Cassiopea on the Swiss Stock Exchange.

Tanner speaks six languages, sits on the board of numerous start-up pharma and medical tech companies, along with the listed companies Cosmo, DKSH and PAION. He is a member of the Wyss Evaluation Board of the University of Zurich and ETH. He studied Macroeconomics at the University of St. Gallen and received a Ph.D. in Economics from the University of St. Gallen in Switzerland.

NEWSROOM

March 19, 2020 Cassiopea announces 2019 Results in line with expectations
chevron right icon
November 13, 2019 Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution
chevron right icon
November 8, 2019 Cassiopea Announces FDA Acceptance of its New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years
chevron right icon
August 20, 2019 Cassiopea Announces FDA Submission of New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years
chevron right icon
July 18, 2019 Cassiopea Announces Results for First Half of 2019
chevron right icon
April 16, 2019 Cassiopea Announces Very Positive Phase II Twelve Months Results for Breezula® (Clascoterone) in Treating Androgenetic Alopecia
chevron right icon
March 26, 2019 Cassiopea Announces Positive Results from Phase III Acne Open-Label Safety Study Evaluating Winlevi® (Clascoterone) Topical Cream for Treatment up to 1 Year
chevron right icon
March 19, 2019 Cassiopea announces results of ordinary and extraordinary shareholders meeting
chevron right icon
February 8, 2019 Cassiopea announces 2018 Results in line with expectations
chevron right icon
October 18, 2018 Cassiopea announces attainment of all primary and secondary endpoints and highly satisfactory safety data in its Phase 3 for Winlevi (Clascoterone) cream in Treating Acne
chevron right icon
October 11, 2018 Cassiopea enters into loan agreement with Cosmo Pharmaceuticals NV
chevron right icon
July 19, 2018 Cassiopea Announces Top Line Positive Proof of Concept Phase II Results for CB-06-02 Immune Modulator in Treating Genital Warts
chevron right icon
July 18, 2018 Cassiopea announces results for first half of 2018
chevron right icon
July 16, 2018 Cassiopea Announces Very Positive Interim Analysis Phase 2 Results for Breezula® (Clascoterone) in Treating Androgenetic Alopecia
chevron right icon
July 10, 2018 Cassiopea Announces Very Positive Top-Line Phase 3 Results for Winlevi® (Clascoterone) cream in Treating Acne
chevron right icon
April 5, 2018 Results of the ordinary and extraordinary shareholders meeting 2018
chevron right icon
March 26, 2018 Lists of candidates for the board of directors at the AGM 2018
chevron right icon
February 28, 2018 Cassiopea reports on financial year 2017 and the development of its clinical programs
chevron right icon
December 11, 2017 Cassiopea announces completion of recruitment of Phase II dose ranging trial of Breezula for androgenic alopecia
chevron right icon
December 7, 2017 Cassiopea announces completion of recruitment of Phase II proof of concept trial of CB-06-02 trial in genital warts
chevron right icon
October 24, 2017 David Hale resigns from Cassiopea’s Board of Directors
chevron right icon
July 21, 2017 Cassiopea announces results for first half of 2017
chevron right icon
April 7, 2017 Cassiopea reports that shareholders approve all agenda items at annual shareholders meeting
chevron right icon
February 24, 2017 Cassiopea reports on financial year 2016 and the development of its clinical programs
chevron right icon
October 18, 2016 Cassiopea announces completion of phase II proof of concept of its novel antibiotic for acne and decision to pursue further development
chevron right icon
July 22, 2016 Cassiopea announces results for first half of 2016
chevron right icon
February 24, 2016 Cassiopea attains clinical endpoints in Breezula® alopecia proof of concept trial
chevron right icon
February 24, 2016 Cassiopea on track with development of its innovative dermatology portfolio
chevron right icon
November 12, 2015 Cassiopea Initiates Phase 3 Clinical Trials of WinleviTM for the Treatment of Acne
chevron right icon
September 24, 2015 Cassiopea announces results for first half of 2015
chevron right icon
August 4, 2015 Cassiopea announces that the FDA has agreed to the Special Protocol for the Winlevi phase III trial
chevron right icon
July 6, 2015 Cassiopea (SIX: SKIN) announces the full exercise of its IPO over-allotment option
chevron right icon
July 1, 2015 Cassiopea prices its IPO at CHF 34 per share and lists on SIX Swiss
chevron right icon
June 22, 2015 Cassiopea announces price range of CHF 30 to CHF 40 per share for its planned IPO
chevron right icon
March 19, 2020
Cassiopea announces 2019 Results in line with expectations
November 13, 2019
Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution
November 8, 2019
Cassiopea Announces FDA Acceptance of its New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years
August 20, 2019
Cassiopea Announces FDA Submission of New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years
July 18, 2019
Cassiopea Announces Results for First Half of 2019
April 16, 2019
Cassiopea Announces Very Positive Phase II Twelve Months Results for Breezula® (Clascoterone) in Treating Androgenetic Alopecia
March 26, 2019
Cassiopea Announces Positive Results from Phase III Acne Open-Label Safety Study Evaluating Winlevi® (Clascoterone) Topical Cream for Treatment up to 1 Year
March 19, 2019
Cassiopea announces results of ordinary and extraordinary shareholders meeting
February 8, 2019
Cassiopea announces 2018 Results in line with expectations
October 18, 2018
Cassiopea announces attainment of all primary and secondary endpoints and highly satisfactory safety data in its Phase 3 for Winlevi (Clascoterone) cream in Treating Acne
October 11, 2018
Cassiopea enters into loan agreement with Cosmo Pharmaceuticals NV
July 19, 2018
Cassiopea Announces Top Line Positive Proof of Concept Phase II Results for CB-06-02 Immune Modulator in Treating Genital Warts
July 18, 2018
Cassiopea announces results for first half of 2018
July 16, 2018
Cassiopea Announces Very Positive Interim Analysis Phase 2 Results for Breezula® (Clascoterone) in Treating Androgenetic Alopecia
July 10, 2018
Cassiopea Announces Very Positive Top-Line Phase 3 Results for Winlevi® (Clascoterone) cream in Treating Acne
April 5, 2018
Results of the ordinary and extraordinary shareholders meeting 2018
March 26, 2018
Lists of candidates for the board of directors at the AGM 2018
February 28, 2018
Cassiopea reports on financial year 2017 and the development of its clinical programs
December 11, 2017
Cassiopea announces completion of recruitment of Phase II dose ranging trial of Breezula for androgenic alopecia
December 7, 2017
Cassiopea announces completion of recruitment of Phase II proof of concept trial of CB-06-02 trial in genital warts
October 24, 2017
David Hale resigns from Cassiopea’s Board of Directors
July 21, 2017
Cassiopea announces results for first half of 2017
April 7, 2017
Cassiopea reports that shareholders approve all agenda items at annual shareholders meeting
February 24, 2017
Cassiopea reports on financial year 2016 and the development of its clinical programs
October 18, 2016
Cassiopea announces completion of phase II proof of concept of its novel antibiotic for acne and decision to pursue further development
July 22, 2016
Cassiopea announces results for first half of 2016
February 24, 2016
Cassiopea attains clinical endpoints in Breezula® alopecia proof of concept trial
February 24, 2016
Cassiopea on track with development of its innovative dermatology portfolio
November 12, 2015
Cassiopea Initiates Phase 3 Clinical Trials of WinleviTM for the Treatment of Acne
September 24, 2015
Cassiopea announces results for first half of 2015
August 4, 2015
Cassiopea announces that the FDA has agreed to the Special Protocol for the Winlevi phase III trial
July 6, 2015
Cassiopea (SIX: SKIN) announces the full exercise of its IPO over-allotment option
July 1, 2015
Cassiopea prices its IPO at CHF 34 per share and lists on SIX Swiss
June 22, 2015
Cassiopea announces price range of CHF 30 to CHF 40 per share for its planned IPO

Breezula is under investigation in the United States for the treatment of androgenetic alopecia, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone solution 7.5% is not FDA-approved.

Winlevi is under investigation in the United States for the treatment of acne, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone cream 1% is not FDA-approved.